Kinomica Ltd.

LONDON, Jan. 14, 2025 /PRNewswire/ -- Kinomica Ltd., a developer of diagnostics for precision oncology, today announced the appointment of Roche Diagnostics' former Global Head of Strategy and Business Development, Dr Michele Pedrocchi as its new Chair of the Board of Directors. With his more than 30 years of successful track record in Life Science and in-vitro Diagnostics and as a former member of the Executive Committee at Roche Diagnostics, Michele has extensive experience and understanding of the growth drivers of a business, including commercial execution and innovation of business models and products. His industry impacting achievements include an instrumental role in establishing polymerase chain reaction (PCR) as a routine diagnostics methodology in Europe and his pioneering role in introducing patient selection for targeted oncology treatments through Companion Diagnostics (CDx), as well as venturing into digital health solutions. Tim Fell, Chief Executive Officer of Kinomica, said: "As an international executive who has brought ground-breaking diagnostic solutions into routine clinical practice, Michele's experience and guidance will be invaluable as Kinomica seeks to do the same with phosphoproteomic diagnostics for therapy selection." Michele Pedrocchi, new Chair of the Board of Directors of Kinomica, commented: "I am thrilled to be taking on this role as Kinomica has great potential for contributing in a fundamental way to truly precision medicine. This world-class team of scientists has made impressive inroads on the promise of phosphoproteomics to guide cancer treatment. Making this proprietary approach and insights widely available is our declared goal." The new Chair appointment follows a financing round led by Mercia Ventures with additional participation from BGF, Longwall Ventures and other existing investors, that sees the company's Board of Directors further strengthen with the appointments of Dr Robert Hornby and Joanna Smart as investor directors for Mercia Ventures and BGF respectively. About Kinomica Kinomica is a developer of precision oncology diagnostics. The company has developed KScan®, a phosphoproteomic diagnostic platform to help clinicians better realize the full potential of precision medicine by predicting which of the drugs currently approved to treat a disease a particular patient will respond best to, thereby aiding clinical decision making. Learn more at and follow us on LinkedIn. Logo - SOURCE Kinomica Ltd. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Predicting patient response to first-line AML treatment using phosphoproteomic data from routine diagnosis samples LONDON, May 29, 2024 /PRNewswire/ -- Kinomica Ltd., a developer of KScan® precision oncology diagnostics, today announces that it will be presenting data on a multi-drug biomarker signature for accurately predicting best first-line treatments in newly-diagnosed acute myeloid leukemia patients at the American Society of Clinical Oncology (ASCO) annual meeting, which will be held May 31 – June 4, in Chicago, IL. "AML is a heterogeneous malignancy with poor prognosis. Several treatments are approved for AML, but clinical trials have shown that current stratification approaches to determine patients' eligibility produce false positives and negatives," said Arran Dokal PhD, CTO of Kinomica. "Here, we used phosphoproteomics to build signatures that accurately predict which of the approved therapies venetoclax plus azacitidine, intensive chemotherapy (IC), or IC plus midostaurin may be more efficacious for a given patient." Details of the poster presentation are as follow: Poster Title: Multi-drug algorithm to accurately predict best first-line treatments in newly-diagnosed acute myeloid leukemia (AML) Presenter: Pedro Rodriguez Cutillas at Barts Cancer Institute Authors: Pedro Rodriguez Cutillas[1], Weronika E. Borek[5], Josie A. Christopher[5], Luis Veiga Nobre[5], Amy Campbell[5], Janet Kelsall[5], Federico Pedicona[5], Nazrath Nawaz[5] , David N. Perkins[5] , Pedro Moreno Cardoso[5] , Andrea Arruda[2], Alexander Joseph Ambinder[3], Sayantanee Dutta[4], Paolo Gallipoli[1], Heinz Sill[4], Gabriel Ghiaur[3], Mark D. Minden[2], Andrew Williamson[5], John G. Gribben[1], Arran David Dokal[5] Organizations: [1] Barts Cancer Institute, [2] Princess Margaret Cancer Centre, [3] Johns Hopkins University, [4] Medical University of Graz, [5] Kinomica Ltd Poster Session: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant Session Date and Time: Monday June 3, 2024, 9:00 AM - 12:00 PM CDT Poster Board Number: 84 Abstract Presentation Number: 6525 The Abstract is available on the ASCO online itinerary planner here. About Kinomica Kinomica is a developer of precision oncology diagnostics. The company has developed KScan®, a phosphoproteomic diagnostic platform to help clinicians better realize the full potential of precision medicine by predicting which of the drugs currently approved to treat a disease a particular patient will respond best to, thereby aiding clinical decision making. Learn more at and follow us on LinkedIn. Logo - SOURCE Kinomica Ltd.

Investigators will present study highlighting a phosphoproteomic diagnostic for patient stratification of first line systemic hepatocellular carcinoma therapy LONDON, May 28, 2024 /PRNewswire/ -- Kinomica Ltd., a developer of KScan® precision oncology diagnostics, today announced the company and collaborators from King's College London and King's College Hospital NHS Foundation Trust will be presenting at the American Society of Clinical Oncology (ASCO) annual meeting, which will be held May 31 – June 4, in Chicago, IL. Debashis Sarker MBChB FRCP PhD, Reader in Experimental Oncology, King's College London and Consultant Medical Oncologist at King's College Hospital, part of King's Health Partners, will present the results of the collaboration in a poster titled ' Identification of a predictive phosphoproteomic signature of response to atezolizumab and bevacizumab (AB) in patients with advanced hepatocellular carcinoma (aHCC)'. Details of the poster presentation are as follow: Poster Session: Developmental Therapeutics—Immunotherapy Session Date and Time: Saturday June 1, 2024, 9:00 AM - 12:00 PM CDT Poster Board Number: 110 Abstract Presentation Number: 2631 "We look forward to sharing our important work that for the first time describes a promising biomarker signature with the potential to predict response to the immunotherapy atezolizumab and bevacizumab in patients with aHCC," said Dr Sarker. "An important characteristic of the study is that the biomarkers have been derived from real-world Tru-Cut biopsies taken at diagnosis providing confidence in their potential clinical utility." "This collaborative effort, drawing on multidisciplinary expertise and rich clinical proteomic data demonstrates the predictive power of the KScan® diagnostic platform," said Tim Fell PhD, Executive Chair of Kinomica. "We look forward to extending this collaborative research to determine predictive biomarkers to other approved aHCC therapies and the creation of a multi-drug diagnostic to aid therapy selection." Kinomica will be attending ASCO. Please contact us to request a meeting. About Kinomica Kinomica is a developer of precision oncology diagnostics. The company has developed KScan®, a phosphoproteomic diagnostic platform to help clinicians better realize the full potential of precision medicine by predicting which of the drugs currently approved to treat a disease a particular patient will respond best to, thereby aiding clinical decision making. Learn more at and follow us on LinkedIn. About King's College Hospital NHS Foundation Trust King's College Hospital NHS Foundation Trust is one of the UK's largest and busiest teaching hospitals. The Trust is recognised internationally for its work in liver disease and transplantation, neurosciences, cardiac, haemato-oncology, fetal medicine, stroke and major trauma. Our hospitals include King's College Hospital (Denmark Hill), the Princess Royal University Hospital (PRUH), and Orpington Hospital – we also provide some services at Beckenham Beacon and Queen Mary's Hospital, Sidcup. We provide care to 1.5 million patients in Southwark, Lambeth, Bromley, Bexley, Lewisham and elsewhere in south-east London and parts of Kent. In 2021, we launched our strategy, Strong Roots, Global Reach, with our new vision to be BOLD. About King's Health Partners King's Health Partners brings research, education and clinical practice together across three NHS Foundation Trusts, Guy's and St Thomas', King's College Hospital, and South London and Maudsley, with a world-leading university, King's College London. We are an Academic Health Science Centre, improving health and care services by translating early scientific research, discoveries and ideas to benefit patients and communities we serve in south London and beyond. We connect people and programmes across our partnership and train and develop future generations of healthcare professionals. Collectively, we serve nearly 40,000 students from 190 countries. Our 45,000 staff conduct around 4.8 million patient visits and we have a turnover of nearly £5 billion. Find out more at kingshealthpartners.org Logo - SOURCE Kinomica Ltd.